ZhenLuo Science

ZhenLuo Science (GYENNO) is a medical AI company focused on Parkinson's disease, founded and led by CEO Ren Kang, whose academic background shaped the company's research-driven DNA . Its flagship offering is 智医灵心, a full-scenario AI system for Parkinson's care, alongside MATRIX Pro, an intelligent assessment platform for neurological diseases . The company is a Qiming Venture Partners portfolio company — Qiming co-led its 100 million RMB B+ round — and has been active on the research front, co-publishing in Nature's npj Digital Medicine with a Kobe University team in 2025 and running a joint neuro-digital-medicine center with Huazhong University of Science and Technology . Per Qiming's reporting, its ambition is to use AI to cut through the "thousand faces, thousand cases" heterogeneity of Parkinson's, and as of September 2025 it was showcasing a full spatiotemporal diagnosis-and-treatment system at the Chinese Medical Association's neurology conference .